Our Affiliate System

We are building one organization with affiliates in two regions. Our parent company, now known as Prisma Health, supports both affiliates with overall direction and leadership as we continue to align. We will soon share one brand across the entire organization to better reflect this. The rebranded Palmetto Health-USC Medical Group will continue to operate as a joint venture between the Midlands affiliate and the USC School of Medicine.

Business Development

Greenville Health System (GHS) is accelerating the development and application of innovative technologies, service lines and healthcare delivery advancements through industry collaborations and strategic business initiatives.

Strategic Partners and Key Relationships

(EIM) is a global health program designed to improve the health and well-being of people in our community through a prescription of physical activity, lifestyle changes and education from physicians and healthcare providers. EIM is committed to establishing physical activity as a standard in health care and is integral in the prevention and treatments of diseases. Greenville Health System (GHS) in partnership with the YMCA of Greenville, the USC School of Medicine Greenville and the American College of Sports Medicine, offers the Exercise is Medicine® program through physicians and healthcare providers to reduce the progression of chronic diseases.

KIYATEC is a life sciences & biotechnology company commercializing innovative three-dimensional (3D) cell culture plasticware and cell-based diagnostics for use in the healthcare, pharmaceutical, and life sciences industries. By combining the best aspects of traditional 2D cell culture with the enormous scientific benefits of culturing cells in 3D, KIYATEC helps researchers better understand and predict complex behavior of cell and tissue systems in vitro – thereby providing a more accurate simulation of phenomena within the human body which allows for improved pharmaceutical research and testing, more precise diagnostic methods and more personalized treatment planning.

Established in 2005 and based in Upstate South Carolina, KIYATEC evolved from research at Clemson University’s Bioengineering Department. The firm is continuing to expand the utility of 3D cell culture technology to further enable research, diagnostic, and treatment advancements.

NUBAD, LLC was founded in 2009 to commercialize the DNA and RNA targeted technologies discovered in the chemistry department at Clemson University. NUBAD, LLC opened up its labs in 2011 at GHS-ITOR in a private sector innovation relationship platform. NUBAD’s goal is to be a leading facilitator in the targeting of nucleic acid based drugs. As new genomic targets are identified, NUBAD’s technologies and probes will assist discovery of DNA and RNA targeted small molecule drugs.

Purilogics, LLC is a privately held membrane technology company based in Greenville, S.C. The company is developing research-scale prepacked, disposable membrane chromatography columns for scientists and engineers who purify biologics for research and early stage drug trials. Our core value proposition is that these column products will improve the speed of early stage development to get biologics to market faster where they are needed to service the large and growing population of patients with long-term, chronic conditions such as cancers, cardiovascular diseases and autoimmune disorders. Market entry will result from the use of these products in research and early stage development laboratories, where rapid drug purification is essential and customers are willing to try new technologies.

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.

TAO Life Sciences invests in and develops early stage medical innovations. Working closely with physicians and researchers from universities and companies, TAO Life Sciences takes new concepts and turns them into reality. TAO Life Sciences is building a pipeline of promising medical device and life science innovations that will impact global healthcare markets and make a significant difference in people’s lives.

TAO Life Sciences applies its expertise to develop prototypes, demonstrate clinical proof of concept and secure financial exits for our innovations. We bring design engineering, scientific direction, and business and legal strategy to clinicians’ and researchers’ new design concepts. In doing so, we have built a diversified pipeline of medical device technologies with significant commercial potential.